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A B S T R A C TIntroduction: Dengue virus infection is the most common arthropod-
borne disease worldwide with approximately 50 to 100 million cases of
dengue infection occurring annually. Globally, dengue incidence has
increased in the last 40 years, especially in Latin American and
Caribbean (LAC) countries where the highest incidence is found. This
systematic review aimed to present information on dengue disease
burden and use of health resources in the LAC region in the last 15
years. Methods: We searched the main international and regional
databases and generic and academic Internet search engines. Gray
literature was retrieved mainly from regional health ministries and Pan
American Health Organization. A set of inclusion criteria was deﬁned.
Results: We identiﬁed 2,041 articles of which 25 met these criteria, 13
for incidence and 12 for the use of resources and related costs. The
pooled incidence of classic dengue fever was 72.1 cases per 100,000see front matter Copyright & 2013, International S
r Inc.
1016/j.vhri.2013.10.002
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ondence to: Ariel Bardach, Institute for Clinical E
CPV, Argentina.persons-years in the 44 LAC countries analyzed (95% conﬁdence interval
71.5–72.7), with an upward trend from 1995 up to 2010. Case-fatality
ratio was highest in 1997 (0.12 [0.05–0.22]) and lowest in 2009, and the
overall mortality was 0.02 per 100,000 people. More than 60% of the
cases in the LAC region came from Brazil. The length of hospital stay
ranged from 5 to 13 days. Conclusions: Activities to control dengue
transmission in the region have been important but insufﬁcient. The
surveillance of dengue burden of disease and circulating strains help
shape and evaluate the present and future health policies.
Keywords: dengue, disease burden, disease costs, epidemiology, Latin
America, resource use.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Dengue virus infection is transmitted primarily by Aedes aegypti
and is the most common arthropod-borne disease worldwide.
There are approximately 50 to 100 million cases of dengue
infection annually. Roughly 2.5 billion people live in endemic
areas that receive around 120 million travelers each year. The
worldwide incidence of dengue and dengue hemorrhagic fever
(DHF) has increased over the last 40 years with an expanding
geographic distribution [1], especially in Latin America [2] The
most important macro determinants responsible for this rise
include increasing population density, poor sanitary conditions
in urban areas, deterioration of public health systems, and lack
of effective vector control programs in many countries. Global-
ization of the economy, international travel, and climatic
changes might also play a role in the spread of the disease [3].
Four types of dengue virus have been identiﬁed up to date:DENV-1, DENV-2, DENV-3, and DENV-4 [4,5]. During the 1960s
and early 1970s, dengue transmission was partially interrupted
in the Americas because of an Aedes aegyptimosquito eradication
campaign designed to prevent yellow fever [6]. Vector surveillance
and vector control measures, however, were not continued and
mosquito reinfestations occurred, causing outbreaks by DEN-2 and
DEN-3 in the Caribbean, Central America, and South America [7]. In
the late 70s and early 80s, DEN-1 and DEN-4 were introduced in
some Latin American and Caribbean (LAC) countries, causing
devastating epidemics [8]. Since then, the region has reported the
highest incidence of cases worldwide (68% of all cases worldwide
from 2000 to 2006), with periodic outbreaks every 3 to 5 years. The
largest occurred in 2002, with more than 1 million reported cases
[9–11]. The average incidence rate of dengue cases reported in these
countries for the period 2000 to 2007 was 71.5 per 100,000 people
annually, and increased in relation to the period 1990 to 1999. The
average incidence rate of DHF was 1.7 per 100,000 for the periodociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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and indirect costs of dengue illness and vector control programs
represent a substantial economic burden on both the health sector
and the overall economy of the region [10]. The high morbidity and
mortality associated with this disease leads to a serious drain on
the economies and the health systems of the affected countries; for
example, a recent study reported a US $2.1 billion average cost due
to the dengue epidemic in the Americas per year [11].
There are two approaches to the prevention and control of
dengue and DHF: vaccines and vector control programs. Unfortu-
nately, vaccines for these viruses are still under development,
and vector control programs are costly and difﬁcult to sustain.
Also, there is little information regarding economic evaluations
of dengue control programs in Latin America and the Caribbean.
To evaluate the cost-effectiveness of new treatment alterna-
tives and the introduction of a vaccine in the region, it is crucial to
count with estimates of the epidemiologic burden of the disease in
LAC countries, taking into consideration incidence, morbidity and
mortality, serotype circulation, and health resource impact. We
conducted a systematic review on dengue disease burden and use
of health resources in the LAC region for the period 1995 to 2010.Methods
Search Strategy and Selection Criteria
We conducted a systematic literature review based on scientiﬁc
literature from international and regional databases, generic and
academic Internet search, and meta-search engines. Databases
containing regional proceedings or congresses’ annals and doc-
toral theses were searched. Web sites from main regional
medical societies, experts, and related associations were con-
sulted. An annotated search strategy for gray literature was
included to retrieve information from relevant sources such as
regional Ministries of Health, Pan American Health Organization
(PAHO), and reports from hospitals.
The search was limited to CENTRAL (The Cochrane Library
Issue 2010), MEDLINE, EMBASE, and LILACS (Latin American and2041 records idenﬁed through
database searching
2041 records screened
435 full-text arcles assessed for
eligibility
34 studies ﬁnally included
- 13 studies were included in meta-analyses
- 9 prospecve studies not included in meta-analyses
- 12 cosng studies and use of resources
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Fig. 1 – Study ﬂowchart. LCaribbean Health Science Literature) between January 1995 and
November 2010. No language restriction was applied. The search
strategy is detailed in Annex 1 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2013.10.002. The reference lists
of articles ﬁnally included were manually searched for additional
information. If data or data subsets of the same population were
published in more than one source, the one with the largest sample
size was chosen. Authors of relevant articles were contacted to
obtain missing or extra information. Epidemiologic outcome meas
ures included incidence, mortality, case-fatality ratio, hospitaliza
tions, and patterns of circulation over time and serotype distribu
tion over time. Economic outcomes included resource usage,
indirect costs, and total costs of epidemics. Studies of any epidemio
logical design, economic evaluations, and costing studies published
were included, when at least 50 cases were evaluated with data
collection from 1995 onwards. Dengue being a disease with man
datory notiﬁcation, all studies providing information at country
level/province level supplemented the ofﬁcial countries’ Ministries
of Health databases (see Annex 3 in Supplemental Materials found
at http://dx.doi.org/10.1016/j.vhri.2013.10.002) and were thus
included for meta-analyses, as long as no evidence of double
counting of cases was detected.
Recently, the traditional World Health Organization dengue
classiﬁcation scheme (classic dengue fever, DHF, and dengue
shock syndrome) was replaced with dengue without warning
signs, dengue with warning signs, and severe dengue. We decided,
however, to stick to the case deﬁnition and classiﬁcation proposed
by PAHO in its epidemiological bulletin because most PAHO data
for the period of interest were reported in that way [12].
Review Methodology
Pairs of reviewers independently selected the articles on the basis
of title and abstract according to prespeciﬁed criteria. During a
second screening process, different pairs of reviewers independ-
ently categorized articles on the basis of retrieved full texts.
Authors of articles were contacted when necessary to obtain
missing or supplementary information. The risk of bias for
observational studies was assessed through the Strengthening1545 records excluded because they
not fulﬁlled the inclusion criteria
61 excluded because full text was not
found
401 Full-text arcles excluded from the
analysis
- 109 contained duplicated data
- 7 with data set <50 cases
- 4 with data before 1995
- 9 immunologic studies
- 177 without primary informaon
- 25 data set with speciﬁc populaons. Not
populaon-level studies
- 14 vector control studies in small cies
- 2 not LA & Caribbean
- 58 studies were used for reference for the
report
A, Latin American.
Table 1 – Characteristics of studies selected to supplement ofﬁcial countries’ MoH databases for meta-analyses.
Author and
reference
Design Population Outcome measures Summary
risk of bias
Salgado et al.
[16]
Design: cross-sectional
hospital-based study
Hospitalized children 0–13 y Number of cases of
hemorrhagic dengue
Low
Setting: Neiva Huila, Colombia Number of deaths
Rigau-Perez
[17,18]
Design: surveillance study
Setting: Puerto Rico
Hospitalized and
ambulatory population
Number of persons with
dengue (classic and
hemorrhagic)
Low
Serotypes
Incidence of dengue/100,000
persons
Ocazionez [19] Design: surveillance study
Setting: Santander, Colombia
General population Number of persons with
dengue
Low
Lyerla [20] Design: surveillance study
Setting: British Virgin Islands
Outpatient population Number of persons with
dengue
Very high
Harris et al. [21] Design: surveillance study
Setting: Nicaragua
Hospitalized and
ambulatory population
Number of persons with
clinical classic dengue
Low
Number of persons with
hemorrhagic dengue
Guzman [22] Design: surveillance study
Setting: Cuba
Hospitalized population Number of persons with
clinical classic dengue
NA
Number of persons with
hemorrhagic dengue
Incidence of classic dengue/
1,000 person-years
Incidence of hemorrhagic
dengue/1,000 person-years
Escobar-Mesa
[23]
Design: ecologic study
Setting: Veracruz, Mexico
Ambulatory patients Number of persons with
clinical classic dengue
Low
Chuit [24] Design: ecologic study
Setting: Argentina
General population Number of persons with
dengue (classic and
hemorrhagic)
Low
Añez et al. [25] Design: surveillance study
Setting: Zulia, Venezuela
Hospitalized population Number of persons with
clinical classic dengue
Moderate
Number of persons with
hemorrhagic dengue
Incidence of classic dengue/
1,000 person-years
Case-fatality rate
Chadee [26] Design: surveillance study
Setting: Trinidad & Tobago
General population Number of persons with
dengue (classic and
hemorrhagic)
Moderate
Incidence of hemorrhagic
dengue/100,000
Anonymous
[27]
Design: surveillance study
Setting: Nicaragua
Children 1–9 y Number of children with
dengue (classic and
hemorrhagic)
Low
Anonymous
[28]
Design: cross-sectional
descriptive
General population Number of persons with
dengue
NA
Setting: Costa Rica, Panama
Avila Montes
[29]
Design: surveillance study
Setting: Honduras
General population Number of persons with
dengue per region
Low
NA, not applicable/available.
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checklist of essential items, modiﬁed according to Sanderson
et al. [14] and Fowkes and Fulton [15]. Brieﬂy, we used analgorithm (see Annex 2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.vhri.2013.10.002) programmed in a
spreadsheet to estimate a summary risk of bias considering ﬁve
Table 2 – Meta-analysis of classic dengue incidence: lethality and mortality and hemorrhagic dengue incidence by country (1995–2009).
Study name Number
of years
Classic dengue
incidence per
100,000 (CI)
Number
of years
Hemorrhagic
dengue
incidence per
100,000 (CI)
Number
of years
Classic dengue
lethality % (CI)
Number
of years
Classic dengue
mortality per
100,000 (CI)
All countries all years 72.1 (71.5–72.7) 1.59 (1.56–1.62) 0.05 (0.05–0.06) 0.02 (0.02–0.02)
By country
American Virgin
Islands
2 4.17 (0.00–12.33) 2 4.17 (4.00 to 12.33)
Anguilla 12 22.0 (9.8–34.1) 7 4.49 (0.09–8.89) 5 2.01 (0.01–7.29) 7 3.94 (0.20 to 8.09)
Antigua & Barbuda 14 6.3 (3.6–8.9) 6 0.62 (0.00–1.33) 4 1.82 (0.00–7.25) 6 0.63 (0.08 to 1.34)
Argentina 11 1.6 (1.2–2.0) 8 0.00 (0.00–0.00) 9 0.02 (0.01–0.04) 9 0.00 (0.00–0.00)
Aruba 9 28.7 (21.3–36.0) 2 0.50 (0.00–1.49) 3 0.28 (0.02–1.44) 4 0.53 (0.20 to 1.26)
Bahamas 11 2.8 (1.4–4.2) 7 0.17 (0.00–0.35) 3 0.20 (0.07–1.36) 6 0.17 (0.02 to0.36)
Barbados 13 162.5 (151.9–173.0) 10 0.17 (0.00–0.35) 8 0.10 (0.03–0.20) 10 0.23 (0.05–0.41)
Belize 13 15.5 (11.7–19.2) 7 0.19 (0.00–0.39) 5 0.14 (0.01–0.73) 5 0.18 (0.04 to 0.41)
Bermuda 10 1.0 (0.2–1.8) 9 0.77 (0.06–1.47) 3 8.14 (0.04–31.81) 8 0.77 (0.02–1.52)
Bolivia 12 107.9 (95.7–120.0) 11 0.30 (0.22–0.38) 10 0.02 (0.01–0.05) 10 0.01 (0.00–0.02)
Brazil 14 196.7 (147.8–245.6) 14 0.62 (0.50–0.74) 14 0.01 (0.00–0.01) 15 0.03 (0.02–0.03)
British Virgin Islands 11 10.8 (4.0–17.6) 8 2.23 (0.04–4.41) 4 3.19 (0.00–12.52) 7 2.23 (0.11 to 4.56)
Cayman Islands 12 2.0 (0.7–3.2) 8 1.16 (0.02–2.31) 4 14.64 (0.21–45.38) 7 1.18 (0.06 to 2.42)
Chile 9 0.2 (0.1–0.3) 6 0.00 (0.00–0.01) 4 0.07 (0.01–0.41) 6 0.00 (0.00–0.01)
Colombia 14 101.9 (82.1–121.6) 14 9.23 (6.98–11.49) 14 0.07 (0.05–0.09) 14 0.07 (0.05–0.08)
Costa Rica 14 297.5 (214.5–380.6) 11 1.52 (1.07–1.98) 11 0.01 (0.00–0.01) 11 0.02 (0.00–0.03)
Cuba 8 12.4 (11.8–13.0) 6 0.19 (0.12–0.25) 4 0.11 (0.00–0.37) 7 0.01 (0.00–0.02)
Curaçao 4 21.9 (12.9–30.9) 2 0.37 (0.00–1.09) 2 0.37 (0.35 to 1.09)
Dominica 13 28.4 (20.3–36.4) 9 1.08 (0.08–2.08) 6 0.46 (0.00–1.73) 7 0.70 (0.03 to 1.43)
Dominican Republic 12 49.7 (36.6–62.8) 15 1.27 (0.88–1.66) 14 0.20 (0.14–0.27)
Ecuador 14 61.4 (45.4–77.4) 9 1.26 (0.85–1.66) 10 0.03 (0.01–0.06) 10 0.01 (0.00–0.02)
El Salvador 14 144.7 (105.9–183.5) 13 2.25 (1.95–2.55) 10 0.09 (0.03–0.18) 10 0.07 (0.04–0.11)
French Guiana 11 1444.1 (1020.2–1867.9) 13 0.64 (0.15–1.13) 7 0.02 (0.01–0.04) 9 0.30 (0.04–0.56)
Grenada 14 24.2 (17.8–30.5) 9 0.57 (0.08–1.05) 4 1.21 (0.00–4.70) 6 0.48 (0.06 to 1.03)
Guadaloupe 11 161.6 (151.5–171.8) 8 1.19 (0.42–1.96) 6 0.05 (0.02–0.11) 7 0.16 (0.02–0.30)
Guatemala 14 46.0 (37.6–54.4) 14 0.13 (0.09–0.17) 10 0.06 (0.04–0.08) 10 0.02 (0.01–0.03)
Guyana 10 15.6 (10.2–21.0) 7 0.08 (0.00–0.15) 4 0.17 (0.00–0.71) 4 0.06 (0.02 to 0.15)
Honduras 14 276.7 (214.4–338.9) 13 14.29 (11.77–16.80) 13 0.03 (0.03–0.04) 13 0.08 (0.05–0.11)
Jamaica 14 14.6 (12.0–17.1) 9 0.14 (0.03–0.24) 8 0.12 (0.04–0.26) 8 0.02 (0.00–0.04)
Martinique 13 435.5 (363.7–507.3) 10 1.74 (0.80–2.68) 7 0.08 (0.04–0.12) 8 0.34 (0.11–0.57)
Mexico 14 24.1 (17.6–30.7) 14 2.11 (1.59–2.63) 11 0.05 (0.02–0.08) 11 0.01 (0.01–0.02)
Montserrat 11 53.0 (16.4–89.6) 9 10.86 (0.80–20.93) 4 5.71 (0.00–21.24) 7 11.08 (0.56 to 22.71)
Nicaragua 14 107.1 (79.7–134.5) 14 5.95 (4.38–7.52) 11 0.16 (0.12–0.20) 11 0.14 (0.08–0.19)
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suring exposure and outcome variables, methods to control con-
founding, design-speciﬁc bias, and statistical methods). Disagree-
ments were solved by consensus. We followed the general guide
lines of the Meta-analysis of Observational Studies in Epidemiol-
ogy [30].
Statistical Analysis
To analyze our data, we conducted proportion meta-analyses.
Arcsine transformations were applied to stabilize the variance of
proportions (Freeman-Tukey variant of the arcsine square-root of
transformed proportions method) [31]. The pooled proportion
was calculated as the back-transformation of the weighted mean
of transformed proportions, using inverse arcsine variance
weights. We applied DerSimonian-Laird weights for the random
effects model [32] when heterogeneity between studies was
found [33]. We calculated the I2 statistics as a measure of the
proportion of the overall variation in the proportion that was
attributable to between-study heterogeneity [34].
The person-time incidence rate, or incidence density rate, is
an appropriate measure of incidence when follow-up times are
unequal [35]. To calculate pooled incidence rate ratios, we used
the Comprehensive Meta-Analysis software package (Biostat,
Englewood, NJ). Speciﬁc type distribution was assessed by age,
country, admission status, and, where possible, patterns of
circulation of strains over different years.Results
We identiﬁed 2041 articles through the search strategy after
removing duplicates. Following the screening by title and abstract,
1545 articles were excluded because they did not meet the
inclusion criteria and 61 because the full text was not available.
A total of 435 studies were classiﬁed as potentially eligible (Fig. 1).
After full-text analysis, 34 studies were deemed to be relevant and
25 were included. Thirteen studies were selected for the meta-
analysis (see Table 1), and 12 studies were included for the use of
resources and related costs analysis [16,21,25,36–43]. Nine prospec-
tive studies with active case detection were excluded from the
meta-analyses because they did not provide country-level infor-
mation; the results of these studies are summarized in the text,
and their characteristics in Annex 4 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.vhri.2013.10.002.
After the methodological quality assessment, 12 included
studies were classiﬁed as low risk of bias and 10 as moderate
risk of bias. The assessment was not applicable in 3 studies (see
Annex 2 in Supplemental Materials found at http://dx.doi.org/10.
1016/j.vhri.2013.10.002). The I2 statistic showed heterogeneity of
more than 70% in the main meta-analyses.
Incidence, Lethality, and Mortality of Classic and Hemorrhagic
Dengue
Incidence of classic dengue was diverse in different parts of the
region for the period studied; meta-analyses for country data are
shown in Table 2. For the period studied, the incidence of classic
dengue per 100,000 was higher in French Guiana (1444.1 [95%
conﬁdence interval (CI) 1020.2–1867.9]), Martinique (435.5 [95% CI
363.7–507.3]), Honduras (2767 [95% CI 214.4–338.9]), Costa Rica
(297.5 [95% CI 214.5–380.6]), and Brazil (196.7 [95% CI 147.8–245.6])
than in the rest of the region, with peaks observed in 1995, 1998,
2000, 2001, and 2009. Regarding the incidence of hemorrhagic
dengue per 100,000, it was found to be higher for the period
considered in Venezuela (15.90 [95% CI 12.46–19.34]), Honduras
(14.29 [95% CI 11.77–16.80]), Montserrat (10.86 [95% CI 0.80–20.93]),
and Colombia (9.23 [95% CI 6.98–11.49]), with peaks in 1997, 1998,
Fig. 2 – South America. Country pooled DF and DHF incidence quintiles (in gradient shading) and relative number of cases in
different years (1995–2008). DF, dengue fever; DHF, dengue hemorrhagic fever.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 2 ( 2 0 1 3 ) 3 4 7 – 3 5 6352and 2009. Chile and Uruguay registered the lowest incidences of
both dengue and hemorrhagic dengue. The distributions of
classic and hemorrhagic dengue pooled incidence by quintiles
in Latin America and the Caribbean countries for the period 1995
to 2010 are depicted in Figs. 2 and 3.
Regarding the incidence of classic dengue from prospective
studies, two studies carried out in Nicaragua reported data from a
cohort of 3800 children aged 2 to 9 years during the years 2004 to
2008 [44,45]; the incidence rate ranged from 343 to 1,759 cases per
100,000 person-years. One study from the municipality of SaoLuis, Sao Paulo, Brazil [46], showed the occurrence of 12,008
notiﬁed cases of dengue disease during 1997 and 1998, with an
incidence of 535.6 and 671.0 per 100,000 people, respectively. Data
from Martinique, French Guyana, showed 560 laboratory-
conﬁrmed dengue cases in a population older than 14 years from
2005 to 2008 [47]. Five studies reported the incidence of dengue
disease in the general population [48–52]. One study [51] reported
2424 cases (incidence rate of 52,67/100,000) in Uberlandia, Brazil,
during 1999; the highest incidence rate was observed in people
aged between 20 and 59 years. Ribeiro et al. [49] reported 3442
Fig. 3 – Pooled DF and DHF incidence quintiles (in gradient shading) and relative number of cases in different years (1995–
2008) in the Caribbean countries. DF, dengue fever; DHF, dengue hemorrhagic fever.
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municipality of São Sebastião, Sao Paulo, Brazil, during the
epidemic of 2001 and 2002. Another study from the State of Sao
Paulo, Brazil [52], reported 14,554 notiﬁed cases (incidence of 381–
432/100,000) mainly affecting the population aged older than 15
years. One study from the city of Iquitos, Peru [50], showed 11
cases (incidence of 9.7/1,000) in a cohort of 1,135 school children
during 2000 and 56 cases (incidence of 11.5/1,000) in a cohort of
4,850 participants during 2004 and 2005. Another study from the
city of Ibague, Colombia [48], reported 232 cases in 1995, 290 cases
in 1996, and 1455 in 1997.
Meta-analyses on lethality (or case-fatality rate) showed that
pooled estimates ranged from 0.01% in Brazil and Peru to 14.6% in
Cayman Islands. Pooled mortality rate ranged from less than 0.01
per 100,000 in Argentina and Peru to 11.08 in Montserrat. High
rates were also found in American Virgin Islands, Anguilla, Turks
& Caicos Islands, and British Virgin Islands (see Table 2).
Health Resources Use Associated With Dengue Disease
Twelve articles provided information about the use of resources
or related costs [16,21,25,36–43]. Table 3 summarizes their char-
acteristics and main outcomes assessed. The mean duration of
the illness in inpatients ranged from 5 to 19 days. The mean
duration range in outpatients was similar. The length of stay in
general wards was 3.8 in Brazil, El Salvador, Guatemala, Panama,
and Venezuela [36] and 4 days in Patillas Puerto Rico [43]. The
length of stay in the intensive care unit was 5 days in a Cuban
study from 2001 [41]. The length of stay for classic dengue in
Nicaragua was 5.7 days and for DHF 6 days [21]; in Peru, it was 3.5
days [40]. One study provided information about the use of
resources or related costs due to dengue disease in Santiago deCuba during 1997 [41]. Direct and indirect costs per dengue case
during 2005 in Brazil, Guatemala, El Salvador, Panama, and
Venezuela for outpatients ranged from US $88 in Guatemala
and El Salvador to US $291 in Brazil. For inpatients, it ranged
between US $418 in Guatemala and US $1065 in Panama [36] (US
$2005). The economic burden of disease during the 2009 epidemic
in Argentina ranged from US $7.1 million to US $10.7 million [38].Discussion
This study analyzes the burden of dengue disease in the LAC
region in the last 15 years. Ofﬁcial sources consisted of ministry
reports and PAHO information including the Dengue Net [53]. The
overall pooled incidence of classic dengue fever was 72.1 cases
per 100,000 person-years in the 44 countries included in the
review considering all years with available data. An increase in
the incidence observed in the region from 1995 up to 2010 has
been highlighted [9].
Between 2001 and 2009, Venezuela, Brazil, Costa Rica, Colom-
bia, Honduras, and Mexico reported more than 75% of all cases in
the region, with Brazil showing the highest number of cases
[54,55]. These data are similar to those of our study. Based on
seroprevalence studies, however, the reported cases represent
only a proportion of the true total number [56]. Some studies
done in the US-Mexican border showed an antibody prevalence of
39% to 50% against dengue, especially in Nuevo Laredo and
Matamorros cities, which represented more than 20 times the
number of cases notiﬁed for the period 1980 to 2007 [57,58].
Dengue has been found to occur in regular cycles with intervals
of 3 to 5 years [59]. Our study shows that the cycles for dengue in
the LAC region in the period studied have been irregular with
Table 3 – Characteristics of costing studies identiﬁed (LAC 1995–2010).
Author Location Denominator Results
Suaya et al. [36] Brazil 2005 Inpatients/ outpatients Length of stay in general bed: 4 d
Mean duration of illness (inpatient): 11 d
Mean duration of illness (outpatient): 12 d
Cost per visit: US $291
Cost per admission: US $676
El Salvador 2005 Inpatients/ outpatients Length of stay in general bed: 3.8 d
Mean duration of illness (inpatient): 11 d
Mean duration of illness (outpatient): 12 d
Cost per visit: US $88
Cost per admission: US $457
Guatemala 2005 Inpatients/ outpatients Length of stay in general bed: 3.8 d
Mean duration of illness (inpatient): 11 d
Mean duration of illness (outpatient): 12 d
Cost per visit: US $88
Cost per admission: US $418
Panama 2005 Inpatients/ outpatients Length of stay in general bed: 3.8 d
Mean duration of illness (inpatient): 11 d
Mean duration of illness (outpatient): 12 d
Cost per visit: US $332
Cost per admission: US $1065
Venezuela 2005 Inpatients/ outpatients Length of stay in general bed: 3.8 d
Mean duration of illness (inpatient): 11 d
Mean duration of illness (outpatient): 12 d
Cost per visit: US $168
Cost per admission: US $627
Armien et al. [37] Panama Province 2005 Children outpatients Mean duration of illness: 18 d
Household cost per visit: US $100
Cost per visit: US $66
Adults outpatients Mean duration of illness (outpatients): 20 d
Inpatients Household cost per visit: US $306
Cost per visit: US $62
Household cost per admission: US $506
Government cost per admission: US $559
Mean duration of illness: 20 d
Household cost per visit: US $269
Government cost per visit: US $63
Direct and indirect costs per case
Inpatients/ outpatients Outpatient: US $332
Inpatients: US $1065
Coudeville et al. [10] Central America and Mexico
2000–2007
Inpatients/ outpatients Direct costs per dengue case: US $323
Andean Sub region 2000–
2007
Inpatients/ outpatients US $373
Brazil 2000–2007 Inpatients/ outpatients US $453
Southem cone 2000–2007 Inpatients/ outpatients US $197
Caribbean 2000–2007 Inpatients/ outpatients US $1244
Hammond et al. [39] Nicaragua, Managua, and
Leon
Inpatient Mean duration of illness: 5 d
Leiva et al. [40] Peru Inpatient Length of stay for dengue hemorrhagic
fever: 3.5 d
Mean duration of the illness: 5 d
Valdés et al. [41] Santiago de Cuba Inpatients Length of stay in intensive care unit: 5 d
Navarro et al. [42] Venezuela Inpatient Mean duration of the illness: 5 d
Salgado et al. [16] Colombia Inpatient Mean duration of the illness: 6 d
Ramos et al. [43] Puerto Rico Patillas Inpatients Length of stay in general bed: 4 d
Harris et al. [21] Nicaragua Inpatient Length of stay for classic dengue: 5.7 d
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frequency.
PAHO began recording serotype circulation in 1995 and since
then all four serotypes have been reported in the LAC region. The
number of countries with more than one circulating serotype hasincreased. As more countries are found to have numerous
dengue serotypes, the probability of secondary infection
increases, leading to a higher risk of both DHF and dengue shock
syndrome [9]. By the end of 2011, PAHO reported more than 1
million cases of dengue fever in Latin American countries, with
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serotypes were circulating by then in the region [2].
The reinfestation of countries that were once free of vector
and the entry of even more virulent viral genotypes have
complicated the situation in the region [60]. DHF epidemics have
become more frequent, reﬂecting a change in the pattern of
dengue viral infections. The countries with the highest incidence
rates of DHF during the study period were Venezuela, Honduras,
Montserrat, Colombia, and Nicaragua; 15.9, 14.2, 10.9, 9.2, and 6.0
per 100,000 person/year, respectively. DHF cases in 2009
increased by more than 50% compared with 1995. While dengue
serotypes in the Americas and Southeast Asia are similar and
endemic in both regions, DHF rates in the Americas are lower
compared with those reported in Southeast Asia [61].
The overall mortality observed in the study period was low
compared with that reported in other regions (0.02 per 100,000
person-years), but the increases in mortality and DHF rates
occurred at the same time within the region. Countries with the
highest reported mortality rates were the Caribbean island
countries, such as Montserrat, American Virgin Islands, Anguilla,
and Turks & Caicos Islands. In the rest of America, Nicaragua,
Honduras, El Salvador, Colombia, Venezuela, and Brazil have the
highest reported mortality with rates of 0.14, 0.08, 0.07, 0.07, 0.04,
and 0.03 per 100,000 person-years, respectively.
Dengue classic fever was analyzed by age group in only four
countries of the region with available data (Bolivia, Brazil, Mexico,
and Colombia). Adults aged 15 to 59 years were the most affected
group. Since 2006, there has been an important increase in the
groups aged 5 to9, 10 to 19, and 20 to 39 in Brazil, with a
worrisome increase in children younger than 5 years. In that
country during 2007 an epidemic change in the age-group proﬁle
of cases was observed; children were increasingly affected with
severe dengue, more closely resembling the epidemiological
proﬁle seen in South-East Asia [62]. Other studies found similar
data, while reports in Venezuela showed a higher incidence in
children since 2005 with a peak in 2007 [25].
According to the 13 articles providing information on the use of
resources or related costs, the mean duration of the illness for
inpatients ranged from 5 days (in Nicaragua, Peru, and Venezuela)
to 13 days (Brazil) and from 9 days (El Salvador) to 20 days (Panama)
for outpatients. Suaya et al. [36] reported in 2009 that an average
episode represented 14.8 lost days for ambulatory patients and 18.9
days for hospitalized patients. The averaged total cost per hospi-
talized case was three times that of an outpatient case. These data
are consistent with those of another study conducted in the period
2005 to 2006 [36]. Variations in costs found in this study may reﬂect
actual local differences in direct costs of treatment, health services,
and wage rates. Dengue poses a heavy economic burden to the
health system and society. A most recent report estimated an
aggregate annual total cost of dengue during the period of 2000 to
2007 of US $2.1 billion for the region [11]. Currently, dengue is
considered ﬁfth in terms of disability-adjusted life-years in the list
of neglected tropical diseases in the Americas [63].
To our knowledge, this is the ﬁrst meta-analysis and system-
atic review with exhaustive information on the burden of disease
and use of resources in the LAC region. As observed in other
studies [11,36,64,65], our analysis has some limitations in esti-
mating the real burden and resource use of dengue disease in the
region. Underreporting of cases, for example, is known to
threaten validity. The differences in illness duration possibly
reﬂected variations in methodologies to assess this outcome. Few
studies examined direct and indirect costs.
Conclusions
During the last 15 years, an increase in DHF and classic dengue
has been observed in many countries. The pattern of intermittentepidemics with long intervals changed to annual outbreaks in
multiple locations and persistent cocirculation of several sero-
types, and situation of hyperendemicity. Young adults were the
most affected in the region, with some countries showing incre-
ments in cases in the pediatric population. To date, activities to
control dengue in the region have been only moderately effective.
It is necessary to improve surveillance and make efforts to reduce
the problem of underreporting. Dengue-endemic countries and
the global public health community need a stronger voice to
persuade society, funding agencies, and policymakers of the
importance of dengue disease.
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